SCHEMBL6140205

SCHEMBL6140205

O=C(O)c1cc([N+](=O)[O-])ccc1N1C(=O)CCC1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.62
SMN1; SMN2 Q16637 4/20 0.62
HTT P42858 3/20 0.56
TDP1 Q9NUW8 2/20 0.56
POLB P06746 2/20 0.56
APEX1 P27695 1/20 0.56
CASP6 P55212 1/20 0.56
CTDSP1 Q9GZU7 1/20 0.56
MAPT P10636 3/20 0.50
CYP3A4 P08684 1/20 0.49
ALOX15 P16050 1/20 0.49
LMNA P02545 3/20 0.47
KMT2A Q03164 2/20 0.46
HPGD P15428 1/20 0.46
MEN1 O00255 1/20 0.46
TP53 P04637 1/20 0.46
CTSV O60911 1/20 0.46
CTSL P07711 1/20 0.46
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15956316 0.88 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2HTTTDP1POLB
SCHEMBL6140211 0.85 LMNA (0.67) ALDH1A1SMN1; SMN2HTTTDP1POLB
SCHEMBL6141764 0.78 TDP1 (0.61) ALDH1A1SMN1; SMN2HTTTDP1POLB
SCHEMBL10502203 0.78 ALDH1A1 (0.97) ALDH1A1SMN1; SMN2HTTPOLBMAPT
SCHEMBL6140662 0.77 CASP6 (0.60) ALDH1A1SMN1; SMN2TDP1POLBAPEX1
SCHEMBL5653191 0.77 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2TDP1POLBAPEX1
SCHEMBL6141689 0.77 POLB (0.60) ALDH1A1SMN1; SMN2HTTTDP1POLB
SCHEMBL6140569 0.77 TDP1 (0.60) ALDH1A1SMN1; SMN2TDP1POLBAPEX1
SCHEMBL6255487 0.77 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2HTTPOLBMAPT
SCHEMBL29805486 0.77 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2HTTPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182260-A1 Process for the preparation of cyclic imides in the presence of polyphosphoric acid MERCK PATENT GMBH (DE) 2005-08-18 US disclosed
EP-1506173-A1 METHOD FOR PRODUCING CYCLIC IMIDES IN THE PRESENCE OF POLYPHOSPHORIC ACID MERCK PATENT GmbH (DE) 2005-02-16 EP disclosed
WO-2003097600-A1 METHOD FOR PRODUCING CYCLIC IMIDES IN THE PRESENCE OF POLYPHOSPHORIC ACID MERCK PATENT GMBH (DE) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182260-A1 Process for the preparation of cyclic imides in the presence of polyphosphoric acid PPIP5K2, ITPA, IPMK ALDH1A1 4132/4885SMN1; SMN2 3960/4885HTT 3233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.